公开(公告)号：US20210275543A1

公开(公告)日：2021-09-09

申请号：US16497704

申请日：2018-03-29

申请人： NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ PARIS DESCARTES ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

发明人： Guillaume CANAUD

IPC分类号： A61K31/553 ,  A61K31/4439 ,  A61P25/28 ,  C12Q1/48

摘要： The invention relates to a method for treating mitochondrial genetic diseases. The inventors have worked with primary fibroblasts from patients and control individuals and collected protein lysates for western blotting. Importantly, they observed that the genetic mitochondrial disorders, show a significant increase in phosphorylation of ribosomal protein S6 (pS6) compared to control fibroblasts, indicative of hyperactivated mTOR signaling. Patients with mitochondrial disorders and controls cells were treated for 48 hours with DMSO or BYL719. All lines from patients with mitochondrial diseases show reduced membrane potential, determined by TMRE staining intensity, and abnormal morphology, fragmentation and the presence of depolarized (low TMRE staining) mitochondria. Treatment with BYL719 attenuated these phenotypes in all MELAS fibroblasts while having no overt impact on the control cells. Similar experiments using flow cytometry confirmed membrane potential (TMRE) rescue by BYL719 treatment in MELAS fibroblasts.

公开(公告)号：US10758610B2

公开(公告)日：2020-09-01

申请号：US16395206

申请日：2019-04-25

申请人： DBV Technologies ,  Assistance Publique Hôpitaux De Paris ,  Université Paris Descartes

发明人： Christophe Dupont ,  Pierre-Henri Benhamou ,  Bertrand Dupont

IPC分类号： A61K9/00 ,  A61K9/70 ,  A61K39/35 ,  A61K39/36 ,  A61K39/00

摘要： The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

公开(公告)号：US10151745B2

公开(公告)日：2018-12-11

申请号：US14646486

申请日：2013-11-21

申请人： INSERM (Institut National De La Santé Et De La Recherche Médicale) ,  Centre National de la Recherche Scientifique (CNRS) ,  Assistance Publique—Hopitaux de Paris ,  Université Paris Descartes ,  Imagine Institut des Maladies Genetiques Necker Enfants Malades

发明人： Olivier Hermine ,  Marie Thérèse Rubio ,  Marie Bouillie ,  Maria Leite de Maraes

IPC分类号： G01N33/50 ,  G01N33/569 ,  G01N33/68

摘要： The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.

公开(公告)号：US20180335435A1

公开(公告)日：2018-11-22

申请号：US15777087

申请日：2016-11-18

申请人： METAFORA BIOSYSTEMS ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ DE MONTPELLIER ,  UNIVERSITÉ PARIS DESCARTES - PARIS V

发明人： Svilena IVANOVA ,  Donatella GIOVANNINI ,  Julien BELLIS ,  Jawida LEZAAR ,  Vincent PETIT ,  Jean-Luc BATTINI ,  Marc SITBON ,  Valérie COURGNAUD

IPC分类号： G01N33/68

CPC分类号： G01N33/6872

摘要： Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and/or BLV infections.

公开(公告)号：US20180296474A1

公开(公告)日：2018-10-18

申请号：US15765854

申请日：2016-10-12

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ PARIS DESCARTES ,  SORBONNE UNIVERSITE ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  FONDATION ASILE DES AVEUGLES

发明人： Francine BEHAR-COHEN ,  Patricia CRISANTI-LASSIAZ

IPC分类号： A61K9/00 ,  A61P27/02 ,  A61K31/551

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.

公开(公告)号：US20170130267A1

公开(公告)日：2017-05-11

申请号：US15125355

申请日：2015-03-17

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  UNIVERSITÉ PARIS DESCARTES ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

发明人： Jean-Paul DUONG VAN HUYEN ,  Xavier JOUVEN ,  Alexandre LOUPY ,  Marion TIBLE

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present invention relates to method for predicting acute rejection in heart recipients. In particular, the present invention relates to a method for predicting acute rejection in a heart recipient comprising the steps consisting of i) determining the expression level (ELi) of at least one miRNAi selected from the group consisting of miR-155, miR-10a, miR-92a and miR-31 in a blood sample obtained from the heart recipient, ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) and iii) and concluding that the recipient has a high risk of developing acute rejection when the level the expression level (ELi) determined at step i) is different (higher or lower) than the predetermined reference level (ELRi).

公开(公告)号：US20160376557A1

公开(公告)日：2016-12-29

申请号：US15125596

申请日：2015-03-19

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Universite Paris - SUD ,  Université de Rennes ,  Université Paris Descartes

发明人： Anne DUBART KUPPERSCHMITT ,  Anne WEBER BENAROUS ,  Anne CORLU ,  Noushin DIANAT

IPC分类号： C12N5/071 ,  A61K35/407

CPC分类号： C12N5/0679 ,  A61K35/407 ,  C12N5/0672 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2501/02 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/12 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/2306 ,  C12N2501/305 ,  C12N2501/385 ,  C12N2501/395 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/14 ,  C12N2506/45 ,  C12N2533/54

摘要： The invention relates to a method for inducing human cholangiocyte differentiation of progenitor cells called hepatoblasts. More specifically, the invention relates to a method for differentiating hepatoblasts to cholangiocytes by culturing said hepatoblasts with a particular medium having interleukin-6 (IL-6) activity. The differentiation method can specifically induce cholangiocyte differentiation from hepatoblasts, and the human cholangiocytes differentiated according to the invention may be useful for drug discovery for treatment of cholangiopathies and bioengineered livers.

摘要翻译： 本发明涉及诱导称为成肝细胞的祖细胞的人胆管细胞分化的方法。 更具体地，本发明涉及通过用具有白细胞介素-6（IL-6）活性的特定培养基培养所述成肝细胞来将成肝细胞与胆管细胞分化的方法。 分化方法可以特异性诱导来自成肝细胞的胆管细胞分化，根据本发明分化的人胆管细胞可用于治疗胆管病和生物工程化肝的药物发现。

公开(公告)号：US20200033349A1

公开(公告)日：2020-01-30

申请号：US16495287

申请日：2018-03-20

申请人： INSERM (Institute National de la Santé et de la Recherche Médicale) ,  Université Paris Descartes ,  Assistance Publique-Hôpitaux de Paris (APHP) ,  Université Paris Diderot - Paris 7

发明人： Pierre-Emmanuel RAUTOU ,  Chantal BOULANGER-ROBERT

IPC分类号： G01N33/574 ,  C07K16/28

摘要： Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.

公开(公告)号：US20190125826A1

公开(公告)日：2019-05-02

申请号：US16095504

申请日：2017-04-21

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA MÉDICALE) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  UNIVERSITÉ PARIS DESCARTES ,  FONDATION IMAGINE

发明人： Christine BODEMER ,  Asma SMAHI ,  Elodie BAL ,  Laura POLIVKA ,  Smail HADJ-RABIA

IPC分类号： A61K38/17 ,  A61P17/00 ,  C12Q1/6883

摘要： The present invention relates to methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency. The inventors show, for the first time, that the structural protein DSG1 directly acts as a novel and unexpected inhibitor of epithelial inflammation via the inhibition of NF-κB signaling pathway. In particular, the present invention relates to a method of treating an inflammatory skin disease associated with desmoglein-1 deficiency in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of restoring the expression of desmogelin-1. Particularly, the inventors carried out the whole exome sequencing, histopathological, electron microscopy, immunofluorescence and immunological analyses in two unrelated patients presenting with SAMEC syndrome.

公开(公告)号：US20190077854A1

公开(公告)日：2019-03-14

申请号：US16191559

申请日：2018-11-15

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DESCARTES

发明人： Patricia Forgez

IPC分类号： C07K16/18 ,  C07K16/30 ,  A61K45/06 ,  C07K16/26 ,  A61K33/24 ,  A61K39/395 ,  A61K39/00

摘要： The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.